Clinical Report: Employing the enhanced liver fibrosis assessment to detect disease in high-risk groups

Overview

This study evaluates the use of the enhanced liver fibrosis (ELF) test and liver stiffness measurement (LSM) in identifying advanced liver disease among high-risk populations, specifically those with type II diabetes and hazardous alcohol use. The findings indicate significant differences in ELF scores and LSM results between these groups.

Background

Steatotic liver disease is increasingly prevalent, particularly among individuals with metabolic risk factors and those with hazardous alcohol intake. Non-invasive tests like ELF and LSM may facilitate earlier detection in at-risk populations.

Data Highlights

Key Findings

• 972 patients were assessed, with 325 undergoing both ELF and LSM tests.
• Patients from the diabetes clinic had higher body mass index and older age compared to those from alcohol services.
• 45% of diabetes clinic patients had ELF scores below 9.5.
• Only 7.9% of diabetes patients undergoing LSM had readings ≥15 kPa.
• 72% of alcohol service patients had ELF scores below 9.5, but 31% had LSM values ≥15 kPa.

Clinical Implications

The study presents data on the use of ELF and LSM in identifying individuals at risk of advanced liver disease in high-risk populations.

Conclusion

The findings highlight the need for effective screening strategies to detect steatotic liver disease early in at-risk populations.

Related Resources & Content

1. The New Gastroenterologist, 2025 -- Addressing NAFLD: Strategies to Alleviate the Effects of Nonalcoholic Fatty Liver Disease
2. Obesity Surgery, 2020 -- Assessment of Liver Function Tests and Risk Scoring for Identifying Significant Liver Disease in Patients Undergoing Bariatric and Metabolic Surgery
3. Obesity Surgery, 2020 -- Evaluation of Noninvasive Tests for Liver Fibrosis in Severely Obese Individuals with Nonalcoholic Fatty Liver Disease
4. Clinical Practice Guidelines, 2024 -- EASL CPGs management of MASLD
5. Diabetes Care, 2025 -- Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes
6. The New Gastroenterologist — Enhanced Risk Assessment Tool May Optimize HCC Monitoring in Cirrhosis Patients
7. ACG Guideline Highlights: Alcohol-Associated Liver Disease (ALD)
8. Clinical Practice Guidelines
9. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association